| 000 | 01525 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250513033122.0 | ||
| 264 | 0 | _c19951212 | |
| 008 | 199512s 0 0 eng d | ||
| 022 | _a0967-0149 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGreenwood, J | |
| 245 | 0 | 0 |
_aEngineering multiple-domain forms of the therapeutic antibody CAMPATH-1H: effects on complement lysis. _h[electronic resource] |
| 260 |
_bTherapeutic immunology _cOct 1994 |
||
| 300 |
_a247-55 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAlemtuzumab |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xchemistry |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Humanized |
| 650 | 0 | 4 | _aAntibodies, Neoplasm |
| 650 | 0 | 4 |
_aAntigens, CD _ximmunology |
| 650 | 0 | 4 | _aAntigens, Neoplasm |
| 650 | 0 | 4 | _aBase Sequence |
| 650 | 0 | 4 | _aCD52 Antigen |
| 650 | 0 | 4 | _aCells, Cultured |
| 650 | 0 | 4 | _aComplement Activation |
| 650 | 0 | 4 | _aCytotoxicity, Immunologic |
| 650 | 0 | 4 |
_aDNA Primers _xchemistry |
| 650 | 0 | 4 | _aDose-Response Relationship, Immunologic |
| 650 | 0 | 4 | _aGlycoproteins |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunoglobulin G _xchemistry |
| 650 | 0 | 4 | _aMolecular Sequence Data |
| 650 | 0 | 4 | _aRepetitive Sequences, Nucleic Acid |
| 650 | 0 | 4 | _aStructure-Activity Relationship |
| 650 | 0 | 4 |
_aT-Lymphocytes _ximmunology |
| 700 | 1 | _aGorman, S D | |
| 700 | 1 | _aRoutledge, E G | |
| 700 | 1 | _aLloyd, I S | |
| 700 | 1 | _aWaldmann, H | |
| 773 | 0 |
_tTherapeutic immunology _gvol. 1 _gno. 5 _gp. 247-55 |
|
| 999 |
_c7583940 _d7583940 |
||